GMP IPO Watch
Goldline Pharmaceutical IPO 2026: SME Pharma Issue Sees Strong Subscription and Positive Market Buzz
Goldline Pharmaceutical IPO has attracted significant investor attention in India’s SME ma...
Read Article
G
SME IPO
LISTED
NSE, BSE
GOLDLINE
Goldline Pharmaceutical IPO
Goldline Pharmaceutical IPO details, live grey market premium (GMP), dates, price band, lot size, subscription & review.
Live GMP Today
₹16.75
+39.0%
Est. Listing: ₹59.75
Price Band
₹41 - ₹43
Per equity share
Lot Size
3000 Shares
Min Invest: ₹2,58,000
Issue Size
₹43 Cr
Total Public Offering
Issue Dates
11 May 2026 – 13 May 2026
Bidding period
Subscription
100.14x
Total overall demand
Goldline Pharmaceutical IPO Details
Key facts at a glance| IPO Open Date | 11 May 2026 | IPO Close Date | 13 May 2026 |
|---|---|---|---|
| Basis of Allotment | TBA | Listing Date | 18 May 2026 |
| Price Band | ₹41 - ₹43 per share | Face Value | ₹10 per share |
| Market Lot Size | 3000 Shares | Min Investment (Retail) | ₹2,58,000 |
| Total Issue Size | ₹43 Cr | Issue Type | Book Built Issue IPO |
| Fresh Issue | — | Offer for Sale (OFS) | — |
| Listing At | NSE, BSE | Issue Category | SME Issue |
| Registrar | TBA | ||
Goldline Pharmaceutical IPO Timetable (Tentative Dates)
| Event | Tentative Date | Status |
|---|---|---|
| IPO Open Date | 11 May 2026 | Confirmed |
| IPO Close Date | 13 May 2026 | Confirmed |
| Basis of Allotment | TBA | Tentative |
| Initiation of Refunds | TBA | Tentative |
| Credit of Shares to Demat | TBA | Tentative |
| IPO Listing Date | 18 May 2026 | Tentative |
| Cut-off time for UPI Mandate Confirmation | 5:00 PM on Closing Day | Deadline |
* Note: Timelines are tentative and subject to regulatory confirmation. UPI mandate approvals must be completed by 5:00 PM on the IPO closing day.
Goldline Pharmaceutical IPO Lot Size & Investment Details
Application limits for Retail and HNI investors| Application Category | Lots | Shares | Amount (at Cut-off) |
|---|---|---|---|
| Retail (Min) | 2 Lots | 6,000 Shares | ₹2,58,000 |
| Retail (Max) | 2 Lots | 6,000 Shares | ₹2,58,000 |
| S-HNI (Min) | 3 Lots | 9,000 Shares | ₹3,87,000 |
| S-HNI (Max) | 7 Lots | 21,000 Shares | ₹9,03,000 |
| B-HNI (Min) | 8 Lots | 24,000 Shares | ₹10,32,000 |
Goldline Pharmaceutical IPO Live GMP & Movement History
Daily unofficial grey market trends
Current Grey Market Premium
₹16.75 +39.0%
Estimated Listing Price
₹59.75
| Date | IPO GMP (₹) | Estimated Listing Price | Estimated Listing Gain (%) |
|---|---|---|---|
| 14 May 2026 | ₹18 | ₹61.00 | +41.86% |
| 13 May 2026 | ₹18 | ₹61.00 | +41.86% |
| 12 May 2026 | ₹17 | ₹60.00 | +39.53% |
Disclaimer: Grey Market Premium (GMP) figures are purely unofficial and indicative rates traded in the unregulated grey market. GMP is highly volatile and does not guarantee the actual listing price. Always consult a SEBI registered investment advisor before bidding.
Goldline Pharmaceutical IPO Subscription Status
Demand breakdown by investor category
Retail
139.51x
QIB
1.31x
NII / HNI
—
Total
100.14x
About Goldline Pharmaceutical
Goldline Pharmaceutical IPO Reservation & Share Quotas
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | 7,32,000 | 27.11% |
| QIB (Ex. Anchor) | 5,40,000 | 20.00% |
| NII | 3,90,000 | 14.44% |
| Retail | 9,00,000 | 33.33% |
Goldline Pharmaceutical IPO Anchor Investors
| Anchor Bidding Date | May 11, 2026 |
|---|---|
| Shares Offered | 7,32,000 |
| Anchor Size | — |
| Lock-in Period (50% Shares - 30 Days) | 2026 |
| Lock-in Period (50% Shares - 90 Days) | 2026 |
Goldline Pharmaceutical IPO Important Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Basis of Allotment | - |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 19 May 2026 |
Note: The timeline for Goldline Pharmaceutical IPO is tentative and subject to change.
Goldline Pharmaceutical IPO Promoters & Holding Pattern
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
| Promoter Holding Post Issue | 96,00,000 | — |
| Promoters |
|---|
| Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal |
Goldline Pharmaceutical Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy.
The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
Goldline Pharmaceutical Company Financial Report
To Be Updated Soon
Goldline Pharmaceutical Company Valuation & Key Performance Indicators
To Be Updated Soon
Goldline Pharmaceutical Peer Group Comparison
To Be Updated Soon
Goldline Pharmaceutical Lead Managers & Merchant Bankers
IPO Lead Managers aka Merchant Bankers
- Cumulative Capital Pvt. Ltd.
Goldline Pharmaceutical IPO FAQs
Goldline Pharmaceutical IPO opens for subscription on 11 May 2026 and closes on 13 May 2026.
The price band for Goldline Pharmaceutical IPO is set at ₹41.00 to ₹43.00 per share.
The minimum market lot size is 3000 shares. A retail investor can apply for a minimum of 1 lot requiring an investment of 6,000 Shares (₹2,58,000).
The latest Grey Market Premium (GMP) for Goldline Pharmaceutical IPO is ₹16.75. GMP represents the unofficial premium at which shares trade prior to listing.
The basis of allotment for Goldline Pharmaceutical IPO is tentatively scheduled for TBA, and shares are expected to list on the stock exchanges on 18 May 2026.
The registrar details will be confirmed in the official prospectus.
Goldline Pharmaceutical IPO Analysis & Articles
